The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Olanzapine Attenuates Mechanical Allodynia in a Rat Model of Partial Sciatic Nerve Ligation

  • Fukuda, Taeko (Department of Anesthesiology, Faculty of Medicine, University of Tsukuba) ;
  • Yamashita, Soichiro (Department of Anesthesiology, Faculty of Medicine, University of Tsukuba) ;
  • Hisano, Setsuji (Laboratory of Neuroendocrinology, Faculty of Medicine, University of Tsukuba) ;
  • Tanaka, Makoto (Department of Anesthesiology, Faculty of Medicine, University of Tsukuba)
  • Received : 2015.04.29
  • Accepted : 2015.06.16
  • Published : 2015.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Neuropathic pain is a global clinical problem; nevertheless, nerve injury treatment methods remain limited. Olanzapine has antinociceptive and anti-nueropathic properties; however, its preventive effects have not been assessed in nerve injury models. Methods: We prepared a partial sciatic nerve ligation (Seltzer model) or sham-operated model in male Sprague-Dawley rats under isoflurane anesthesia. In a pre-treatment study, we administered olanzapine (10 mg/kg) intraperitoneally 1 h before nerve ligation. In post-treatment and dose-dependent studies, we injected 3 different doses of olanzapine intraperitoneally 1 h after nerve ligation. Mechanical allodynia was measured before and 7 days after surgery. Immunohistochemical analysis using anti-Iba-1 antibody was used to assess the effect of olanzapine at the spinal level. Results: In the pre-treatment study, median withdrawal thresholds of the normal saline groups were significantly lower than those of the sham-operated groups; however, those of the olanzapine (10 mg/kg) and sham-operated groups were not different. In the post-treatment and dose-dependent studies, the median withdrawal thresholds of the olanzapine (2.5 mg/kg) and normal saline groups were not different; however, those of the olanzapine (10 and 50 mg/kg) groups were significantly higher than those of the normal saline groups. Olanzapine did not have a significant effect on the density of Iba-1 staining. Conclusions: Olanzapine attenuated mechanical allodynia dose-dependently in the Seltzer model. This anti-allodynic effect of olanzapine was observed even when injected 1 h after nerve ligation. This effect of olanzapine appeared to be unrelated to microglia activation in the ipsilateral dorsal horn of the lumbar spinal cord.

Keywords

References

  1. Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton LJ 3rd. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. Pain Med 2009; 10: 586-93. https://doi.org/10.1111/j.1526-4637.2009.00588.x
  2. Lecomte F, Gault N, Kone V, Lafoix C, Ginsburg C, Claessens YE, et al. Prevalence of neuropathic pain in emergency patients: an observational study. Am J Emerg Med 2011; 29: 43-9. https://doi.org/10.1016/j.ajem.2009.07.009
  3. Johansen A, Romundstad L, Nielsen CS, Schirmer H, Stubhaug A. Persistent postsurgical pain in a general population: prevalence and predictors in the Tromso study. Pain 2012; 153: 1390-6. https://doi.org/10.1016/j.pain.2012.02.018
  4. Lee JB, Choi SS, Ahn EH, Hahm KD, Suh JH, Leem JG, et al. Effect of perioperative perineural injection of dexamethasone and bupivacaine on a rat spared nerve injury model. Korean J Pain 2010; 23: 166-71. https://doi.org/10.3344/kjp.2010.23.3.166
  5. Jung KT, Lee HY, Yoon MH, Lim KJ. The effect of urinary trypsin inhibitor against neuropathic pain in rat models. Korean J Pain 2013; 26: 356-60. https://doi.org/10.3344/kjp.2013.26.4.356
  6. Moini Zanjani T, Ameli H, Labibi F, Sedaghat K, Sabetkasaei M. The attenuation of pain behavior and serum COX-2 concentration by curcumin in a rat model of neuropathic pain. Korean J Pain 2014; 27: 246-52. https://doi.org/10.3344/kjp.2014.27.3.246
  7. Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, et al. Olanzapine: a basic science update. Br J Psychiatry Suppl 1999: 36-40.
  8. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61 Suppl 3: 16-21. https://doi.org/10.4088/JCP.v61n0105
  9. Schreiber S, Getslev V, Backer MM, Weizman R, Pick CG. The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharmacol Biochem Behav 1999; 64: 75-80. https://doi.org/10.1016/S0091-3057(99)00107-0
  10. Kiser RS, Cohen HM, Freedenfeld RN, Jewell C, Fuchs PN. Olanzapine for the treatment of fibromyalgia symptoms. J Pain Symptom Manage 2001; 22: 704-8. https://doi.org/10.1016/S0885-3924(01)00302-5
  11. Khojainova N, Santiago-Palma J, Kornick C, Breitbart W, Gonzales GR. Olanzapine in the management of cancer pain. J Pain Symptom Manage 2002; 23: 346-50. https://doi.org/10.1016/S0885-3924(02)00378-0
  12. Silberstein SD, Peres MF, Hopkins MM, Shechter AL, Young WB, Rozen TD. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache 2002; 42: 515-8. https://doi.org/10.1046/j.1526-4610.2002.02126.x
  13. Gorski ED, Willis KC. Report of three case studies with olanzapine for chronic pain. J Pain 2003; 4: 166-8. https://doi.org/10.1054/jpai.2003.438
  14. Rico-Villademoros F, Hidalgo J, Dominguez I, Garcia-Leiva JM, Calandre EP. Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 161-4. https://doi.org/10.1016/j.pnpbp.2004.08.012
  15. Freedenfeld RN, Murray M, Fuchs PN, Kiser RS. Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic. Pain Pract 2006; 6: 112-8. https://doi.org/10.1111/j.1533-2500.2006.00072.x
  16. Torigoe K, Nakahara K, Rahmadi M, Yoshizawa K, Horiuchi H, Hirayama S, et al. Usefulness of olanzapine as an adjunct to opioid treatment and for the treatment of neuropathic pain. Anesthesiology 2012; 116: 159-69. https://doi.org/10.1097/ALN.0b013e31823c7e56
  17. Tsuda M, Inoue K, Salter MW. Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia. Trends Neurosci 2005; 28: 101-7. https://doi.org/10.1016/j.tins.2004.12.002
  18. Ji RR, Suter MR. p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain 2007; 3: 33. https://doi.org/10.1186/1744-8069-3-33
  19. Talbot S, Chahmi E, Dias JP, Couture R. Key role for spinal dorsal horn microglial kinin B1 receptor in early diabetic pain neuropathy. J Neuroinflammation 2010; 7: 36. https://doi.org/10.1186/1742-2094-7-36
  20. Chu YX, Zhang YQ, Zhao ZQ. Involvement of microglia and interleukin-18 in the induction of long-term potentiation of spinal nociceptive responses induced by tetanic sciatic stimulation. Neurosci Bull 2012; 28: 49-60. https://doi.org/10.1007/s12264-012-1058-4
  21. Mika J, Osikowicz M, Rojewska E, Korostynski M, Wawrzczak- Bargiela A, Przewlocki R, et al. Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain. Eur J Pharmacol 2009; 623: 65-72. https://doi.org/10.1016/j.ejphar.2009.09.030
  22. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990; 43: 205-18. https://doi.org/10.1016/0304-3959(90)91074-S
  23. Meyer JM, Simpson GM. From chlorpromazine to olanzapine: a brief history of antipsychotics. Psychiatr Serv 1997; 48: 1137-9. https://doi.org/10.1176/ps.48.9.1137
  24. Wang HH, Xu SF. Effect of D1 and D2 dopamine receptor antagonists on acupuncture analgesia. Sheng Li Xue Bao 1993; 45: 61-8.
  25. Aravagiri M, Teper Y, Marder SR. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 1999; 20: 369-77. https://doi.org/10.1002/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6
  26. Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 2003; 28: 1-13. https://doi.org/10.1038/sj.npp.1300015
  27. Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma 2005; 22: 106-18. https://doi.org/10.1089/neu.2005.22.106
  28. Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG. Allopregnanolone prevents and suppresses oxaliplatinevoked painful neuropathy: multi-parametric assessment and direct evidence. Pain 2011; 152: 170-81. https://doi.org/10.1016/j.pain.2010.10.015
  29. Kawano T, Soga T, Chi H, Eguchi S, Yamazaki F, Kumagai N, et al. Role of the neurosteroid allopregnanolone in the hyperalgesic behavior induced by painful nerve injury in rats. J Anesth 2011; 25: 942-5. https://doi.org/10.1007/s00540-011-1216-2
  30. Kuner R. Central mechanisms of pathological pain. Nat Med 2010; 16: 1258-66. https://doi.org/10.1038/nm.2231
  31. Zhang G, Terry AV Jr, Bartlett MG. Sensitive liquid chromatography tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 858: 276-81. https://doi.org/10.1016/j.jchromb.2007.08.007
  32. Maier C, Baron R, Tolle TR, Binder A, Birbaumer N, Birklein F, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 2010; 150: 439-50. https://doi.org/10.1016/j.pain.2010.05.002

Cited by

  1. Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration vol.32, pp.4, 2017, https://doi.org/10.1002/hup.2604
  2. Proof-of-Concept for the Analgesic Effect and Thermoregulatory Safety of Orally Administered Multi-Target Compound SZV 1287 in Mice: A Novel Drug Candidate for Neuropathic Pain vol.9, pp.7, 2021, https://doi.org/10.3390/biomedicines9070749